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INTRODUCTION
Malignant cells are characterized by the ability to invade surrounding normal tissues. Tumor invasion is
abetted by proteolytic enzymes that have been correlated with recurrent disease and metastasis. These
enzymes are involved in a cascade of proteolytic interactions with other enzymes and inhibitors which
allow cancer cells to dissolve surrounding extracellular matrix, thereby enabling the cells to rapidly invade
adjacent tissues and migrate to metastatic sites distant from the primary tumor. Among these proteases
are the plasminogen activators (PA), collagenase IV, laminase, and in some cases cathepsin D, which
together mediate key steps in the invasion process of metastasis.
Cells which have the selective advantage for invasion and metastasis are those capable of regulating their
proteolytic activity and proliferation. Cells in the process of invasion would be probably down-regulated for
proliferation, but subsequent to attachment and adhesion at a distant site, would then be in a proliferative
mode, up-regulating DNA replication.
Urokinase (uPA) can be present in the tissues in several molecular forms. The inactive proenzyme is a
single chain protein (scuPA) that is cleaved at Lys.158 to form the double chain, high molecular weight
active form (HMW-uPA) of 54 kD. A low molecular weight form (LMW-uPA) can also be produced by
cleavage of the HMW-uPA at Lys.135 - Lys.136 giving a 35 kD active enzyme. Recently, it has been
shown that the HMW active form of urokinase, bound to the tumor cell membrane, is responsible for the
local lysis of the extracellular matrix, hence the tissue invasion mechanism for metastasis [Andreasen et al,
1986]. Receptor- (membrane) bound uPA is twice as efficient (catalytically) as free fluid-phase uPA [Hollas
et al, 1991]. The unbound uPA and the LMW form is not responsible for most of the local dissolution of
extracellular matrix in the immediate vicinity of the metastatic tumor cell.
High levels of urokinase (>3.49 ng/mg of total protein) extracted from breast tumor tissues have recently
been shown, together with plasminogen activator inhibitor 1 (PAl-l), to be a good prognostic indicator for
high risk of recurrence and shorter patient survival times [Janicke et al, 1991; Duffy et al, 1991; Grendahl-
Hansen et al, 1993].
In this project, we have attempted to develop immunocytochemical methodologies for the clinical
assessment of the expression of urokinase plasminogen activator, which has been implicated to be
important for initial steps in tumor invasion, and to relate it to cell proliferation and DNA replication at the
single-cell level.
Flow cytometric studies of urokinase in cultured qlioma cells:
In order to establish the parameters for immunofluorometric analysis of urokinase (uPA) in tumor cells,
studies were initiated with human glioma cell lines, which have been found to produce high levels of uPA.
These studies involve both flow cytometry (FCM) and image analysis; the FCM studies permit the
correlation of urokinase expression with the cell cycle, while with image analysis one can localize and
quantitate uPA in the cytoplasm and cell membrane. Another advantage of the use of cell lines is the
ability to study uPA expression in relation to cell proliferation and DNA replication.
Three cell lines have been employed in the studies thus far, all from Dr. Marylou Ingram, Huntington
Research Foundation, Pasadena, CA. The three cell lines, which were cultured from patient surgical
biopsy material, have different morphological characteristics and growth rates. While alterations in the cells
obviously occur in culture, the consistent morphology of these cell lines during passage in culture
encourages us to pursue differences in the cell's characteristics, which will hopefully shed some light on
the relationship of uPA to the biological behavior of the original tumors.
The first of these lines, CS, grows very rapidly as polygonal cells in monolayers and in the absence of
serum, tends to form spheroid structures. The second cell line, HBr09, has a fibroblastoid morphology but
has the characteristic immunological marker associated with gliomas, glial fibrillary acidic protein (GFAP,
Patau,1988) This cell line grows at about one quarter the rate of CS. A third line, HBr65, was employed for
some studies of uPA expression coupled with DNA replication, as well as uPA localization.
Combined anti-uPA and anti-BrdUrd immunostaininq for uPA and DNA replication at the sinqle-cell leveh
These studies were performed with the cell line, HBr65, also obtained from glioma patients and initiated in
primary culture by Dr. Ingram. Cell monolayers were pulsed with IdUrd and dual immunofluorescence
staining performed for detection of both iododeoxyuridine (IdUrd) and urokinase. The protocol,
developed under this contract in our laboratories, is described below in the METHODS section.
Immunocytochemical Studies of Breast Cancer Biopsies:
In this project, biopsies from these women, who have previously been diagnosed with node negative
breast cancer, are being analyzed by immunohistochemical, flow and image cytometry techniques in
order to correlate specific tumor markers with clinical outcome for each patient.
METHODS
Cell culture of glioma lines:
Cells were grown in 1:1 DMEM:F12 medium containing 15 % fetal bovine serum. The growth medium was
replaced with a "production medium" without serum at the point when the cells appeared to be nearly
confluent.
For flow cytometry, cells were scraped from flasks, in lieu of trypsinization, in order to preserve membrane-
bound antigen. Cells were then washed in PBS and triturated to disperse the cell clumps. Single-cell
suspensions were usually achieved, which were then fixed for 15 min in 0.5% paraformaldehyde at room
temperature, followed by one hour permeabilization in 70% methanol at 4° C. The cell suspensions were
blocked with 1% bovine serum albumin in PBS for 15 minutes, cells were then washed in PBS and
antibody titered by staining with increasing dilutions of the primary, anti-uPA monoclonal antibody (#394,
obtained from American Diagnostica, Greenwich,CT), or the equivalent concentrations of naive mouse
IgG2a, both diluted in 1% BSA in PBS. Staining was for one hour, cells were washed and incubated in
second antibody, fluorescein-conjugated goat anti-mouse IgG, for flow and image cytometry studies, or
rhodamine-labeled goat anti-mouse IgG (ICN, Irvine, CA) for image cytometry, diluted in 4% goat serum for
one hour. In later experiments, cells were pre-incubated for one hour in 4% goat serum in PBS prior to
addition of the second antibody. The immunostained cells were then incubated in ribonuclease (1 mg/ml
in PBS) for 30 min and stained for DNA content with 15 pg/ml propidium iodide.
Flow cytometric analysis :
Row cytometric analysis was conducted with a EPICS Profile flow cytometer (Coulter Corporation, Hialeah
FL with the 488 nm line of an argon laser. Green light (from fluorescein emission) passed through a narrow
bandpass interference filter (520 +/- 10nm), while red light (from PI) was passed through a 630 long pass
filter. Bivariate, 64 x 64 channel histograms were obtained for analysis of mean fluorescence intensity.
Data also were normalized for area and fluorescence intensity after the background was subtracted. This
allowed comparisons among cells from the same samples and comparisons between cell lines and
different samples. Statistical analysis of the data was performed by multivariate analysis using Statview 512
(Abacus Concepts, Inc.)
Dual, anti-uPA/anti-BrdUrd experiments:
These were performed by pulsing tissue culture chamber slides with 10 HM IdUrd for 60 min, and fixing the
cell monolayers with 1% paraformaldehyde/.01% Tween 20. Immunostaining for both uPA and IdUrd
incorporation was performed by treating the monolayers with DNase (1 mg/ml) prior to immunostaining for
uPA by the indirect technique, and then with direct, anti-BrdUrd fluorescein conjugate (Gratzner HG,
1982).
Digital image analysis :
Image analysis was performed using a fluorescence microscope equipped with a Dage SITS high
resolution video camera connected to a QuickCapture board (Data Translation, Inc.) and NIH Image using
the Macintosh Ilfx. Images were stored as TIFF files and later analyzed using NIHImage Version 41.1.
Individual cells were scanned for mean optical densities and normalized for area. Relative fluorescence
was compared after subtracting any background or autofluorescence measured from control cells on the
same slide. Areas of concentrated uPA, within the cell and bound to the cell membrane were further
analyzed by density slicing and thresholding followed by particulate analysis of those specific areas.
Confocal microscopy :
Confocal microscopy was performed with a Zeiss laser confocal microscope system in the laboratory of Dr.
Michael Andreeff, M.D. Anderson Cancer Center, Department of Hematology. uPA was localized by
excitation with a helium/neon laser. Serial sections of 250nm thickness were acquired and assembled into
sequential, serial sections by software supplied with the confocal microscope.
Fluorescence in situ hybridization: (FISH)
Human glioma cells, HBr65, were trypsinized from tissue culture flask monolayers, centrifuged onto
microscope slides, fixed in methanol acetic acid (3:1) and air dried. FISH was performed by standard
methodology: the Internally-labeled alpha satellite probe for human chromosome # 10 purchased from
Imagenetics, Inc. was denatured and employed according to instructions included with the FISH kit.
Fluorescent images were photographed with a Zeiss Photomicroscope II using a planoapochomatic 63X
objective (NA 1.25) on Kodak High Speed Ektachrome P800/1600 film.
Breast tumor immunohistochemistry:
Paraffin blocks were supplied by the OCOG Node Negative Breast Cancer Group through Dr. Harvey
Cramer, London Ontario Regional Cancer Centre. Sections were cut, deparaffinized by usual procedures
and stained by immunoperoxidase methodology. Tumor grading was by our pathology consultant, Dr.
Ruth L. Katz, M.D. Anderson Cancer Center.
Results and Discussion.
Flow cytometric analysis:
Flow cytometry was performed by two-color analysis, with combined immunofluorescence for uPA and
DNA content by PI staining. Two parameter histograms are shown in Figure 1 for both cell lines as studied
by FCM. As expected, the majority of the uPA expression is found in the G1 compartment of the cell cycle,
since the cells were primarily in stationary phase, having been transferred to serum-free conditions.
Attempts have been made to study the expression of uPA during exponential growth as well as in cultures
that have been placed in serum-free medium. We conducted flow cytometric analysis of uPA levels in both
CS and HBr09 glioma lines. In Table 1 are the relative levels of the uPA as measured by flow
immunofluorescence. Further studies are concerned with measurements of uPA by image cytometry, in
an effort to distinguish the membrane-bound (receptor) vs cytoplasmic uPA, since flow cytometry only
measures fluorescence at "zero resolution".
Both cell lines produce uPA during growth and also during stationary phase. HBr09 produces significantly
higher levels of intracellular and membrane-bound uPA. The CS line reveals two G1 populations, low and
high uPA- expressing G1 cells, possibly reflecting residual proliferation in the culture. The HBr09 cell line
in contrastshowsonlyhighuPAcontentG1cellsandwitha five-foldgreaterexpressionof cell-bound
uPAof thantheuPAexpressingpopulationof theCSline.It is to benotedthatHBr09growsextremely
slowly,and also representsa low-passage(passage13)glioblastomaline, whereasCS is highly
proliferating,and hasbeenincultureandwhileispositiveforGFAPantigen,isofunknownorigin.
Urokinase Localization by Confocal Microscopy:
Confocal microscopy (CFM) is an invaluable technique for localizing substructures and molecules at the
microscopic level, and permits three-dimensional visualization. In Figure 2 are shown serial optical sections
of an HBr65 cell monolayer which has been immunofluorescently stained for urokinase andexamined by
means of CFM. The cell surface as well as cytoplasmic localization of uPA is apparent by these procedure.
Similar confocal microscopic analysis of urokinase receptor (uPAR) exhibits the same localization on cell
membranes (not shown).
Image Analysis:
Image cytometry provides a method for the spatial quantitation of uPA. The relative amounts of the
enzyme in various cell compartments can be determined in a manner obviously not possible by flow
cytometry. In Figure 3 is shown a fluorescence micrograph of a CS cell which as been immunostained for
uPA. Note that the fluorescence is expressed as a large cap on the cell surface. Figure 4 represents a
digitized image of a similar field which dramatically shows the distribution of uPA on the membrane as well
as within the cells and demonstrates how uPA levels can be spatially quantified.
In Table 1, the distribution of uPA antigen between these locales is displayed. The levels of uPA
determined by FCM for these two cell lines is reflected in this image cytometry data, but now the relative
amounts within and on the cell membranes can be measured. Interestingly, the overall magnitude of uPA
levels is the same, but now is composed of membrane plus cytoplasmic fluorescence. The uPA is
predominantly observed to be on the cell surface.
COMPARISON OF UROKINASE IN GLIOMA CELLS
MEAN
CELLLINE FEJJ,L0.B,_C_ S.D. BOUND uPA S.D.
FLOW
CYTOMETRY
IgG 2.05 0.3
CS 6.13 0.1
HBR09 32.25 11.3
RATIO HBR09/CS = 7.411
IMAGE
ANALYSIS
IgG 1.86 0.1
CS 11.3 0.76 (8%)
HBR09 74.1 6.34 (9%)
RATIO HBR091CS = 7.56 I1
78.3 3.41 (4%)
821.9 47.8 (6%)
HBROg/cs = 10.5/1
Combined urokinase expression and DNA replication:
In Figure 5 are shown fluorescence micrographs representative of the 2-parameter immunostaining for
uPA and DNA replication. While no immediate correlation has been observed between replication and
uPA expression, the immunolocalization of uPA can be seen to be, as expected, on cell membranes and
in the cytoplasm. The nuclei are fluorescent as expected for immunostaining for IdUrd incorporation that is
indicative of DNA synthesis. No correlations between DNA replication and uPA expression, either
cytoplasmically or on cell membranes, are apparent from our studies thus far.
Cytogenetic analysis of glioma cells by FISH:
Since we have shown uPA to be over-expressed in HBr65 and the structural gene for uPA is located on
chromosome10 (Verde et al, 1984), numerical chromosome alteration analysis for chromosome 10 was
performed on this cell line. As shown in Figure 6, multiple copies of chromosome 10 appear to be
present, as determined by FISH with the metaphase alpha satellite probe which is specific for this
chromosome. Controls consisting of normal human lymphocytes placed on the same slides and probed
simultaneously are diploid (Figure 6b).
Ontario Clinical Oncology (OCOG) Breast Cancer Study
CTI, Inc./DNA Sciences, Inc. in collaboration with the Ontario Clinical Oncology Group(OCOG) Breast
Cancer Study, Ontario, Canada, is conducting a study of approximately 650 patients with breast cancer.
The patients in this study were subjected to various combinations of radiation therapy and lumpectomy in
an effort to establish the efficacy of radiotherapy and surgery. In this project, biopsies from these women,
who have previously been diagnosed with node negative breast cancer, are being analyzed by
immunohistochemical, flow and image cytometry techniques in order to correlate specific tumor markers
with clinical outcome for each patient. This study represents an invaluable opportunity, for additional
research funding in addition to the use of the material for screening of new prognostic probes for cancer.
In this NASA-supported study, we employed these biopsies for analyzing markers for metastasis, in order
to correlate them with urokinase plasminogen activator, or to ascertain whether urokinase is an
independent determinant The latter has been determined recently in other institutions to be a significant
predictor of time-to-relapse and disease-free survival in node negative breast cancer [Janicke et al, 1991;
Duffy et al, 1991; GrendahI-Hansenet al, 1993].
In Table 2 are the tumor and proliferation markers we have employed for the OCOG specimens
Tumor Markers Tested for OCOG Breast Cancer Study
Marker Function Reference
Urokinase protease Grondahl/Hansen et al, 1993;
Janicke et al, 1991.
Her 2/neu trans-membrane Slamon et al, 1989
(c erb 2) oncogene
p53 tumor suppressor Oren, 1992
gene
PCNA DNA synthesis McGuire WL, 1990
accessary protein
Evaluationsof anti-uPAlabeled breast cancer sections reveal that normal breast tissue does not contain
uPA except for some endothelial cells lining the arterioles. Intraductal carcinomas, however, do express
measurable quantities of uPA using immunoperoxidase detection methods.
Measurements of uPA by absorption of immunologic stains as light passes through tumor cells usually is
recorded by the image analysis system as the mean optical density of groups of cells in the field of view.
While this is more difficult to quantitate, especially for individual cells, since light absorbed by the
histopathology counterstains add to the absorption of the uPA antibody labels, this is the current method
employed in pathology laboratories. Measurements of fluorescence is a better quantitative method since
the light is emitted only from the uPA molecules and it is emitted at a wavelength different from the
incident light. Also fluorescent stains are used at lower concentrations than are absorbing stains and the
net background from autofluorescence is less than the contribution of non-specific staining by light
absorbing stains [Lockett SJ et al, 1991].
Figure 7a shows an example of a breast tumor section immunostained by the immunoperoxidase
technique, illustrating the areas of uPA found in foci of tumor cells. A normal kidney section has been
stained for a positive control.The images are a digital representation of the immunostained sections.
Distinct areas of concentrated uPA are shown (dark areas). Most of the normal tissue does not produce
urokinase. Figure 7 b shows the same section, but subjected to "digital slicing" protocol of the NIH Image
software. The red areas are of equivalent mean optical density (MOD), demonstrating the process by
which we will conduct quantitative image cytometry for clinical specimens in future studies and for our
clinical laboratory breast cancer panel.
These methods can be used in retrospective studies where the time to reoccurrence, degree of
metastasis and morbidity are known. Cumulative data then can be used to provide a prognostic indicator
for the presence of active metastasis.
In Table 3 are shown a summary of the data obtained from this study, as performed by immunohistological
staining.The results of the studies with these patients will be applied to our breast cancer prognostic panel
offered to physicians.
Summary of OCOG Node Negative Breast Cancer Data
BLOCK UPA
86-591 1
87-596 3
86-1798FS1 0
87-1838 0
86-1914_S 2
85-2216A 3
86-3308A 1
86-3311 1A 2
84-9729 1 1
84-3602 FS 2
86-3969_S 2
86,-4220_S 1
85-4541qs 2
85-4580 B 0
84-4642 Q3 1
85-5307A 1
86-$301A 3
87-5475_8 2
85-5535 1
86-8905F8 1
84-6208 0
87-6508 A3 3
86-6695 A 2
85-7296FS 3
874-7467 FS 2
87-8159 _S 1
84-9277 3
87-9522qS 3
85-10589q 0
84-10767 2
85-11331_S 2
84-119441 1
85 239 1
86-591 |
87-$96FS 3
88-1096 1
89-1560 1
86-2450 E 2
88-2941_S 1
88-3000 A 0
87-3137 A 0
88-369281 1
88-3895 3
85 5452 A 2
88-5768 2
85 7478 A 1
89-10179 3
88-10970 IA 0
88-11077 3
87 1244 2
86 1275 A 2
88 2321 A 0
87 2936 A 2
863111A 0
87 3176 3
86 3582 A 1
85 $169 2
87 9726 2
395 0
896 1
1244 2
t275 2
1596 1
1717 3
2321 0
2716 3
3137 0
3160 3
3506 1
3786 3
3999 0
4005 I
4066 0
74281 2
5350 1
5452 2
7224 0
7271 0
7467 2
7478 I
7544 0
8706 2
10299 3
HISTOLOGY
D 1
0 2
0 1
DCIS/C+NC 1
0 1
L 2
L 1
D 1
D 1
0 3
D 1
O/TUBULAR 3
D 1
D 1
D/TUBULAR 3
D 1
D 2
LOBULAR 3
DCIS/C 7 INV 2
0 1
D/T 3
LOBULAR 2
D I
D/TUBULAR 3
) POORFD(ATION 1
D 3
D 1
LOB 2
0 I
D I
D I
D 2
D I
no tumour
0 2
0 I
0 1
0 1
0 I
D 1
0 1
D 3
D 1
2
D 1
D 1,2
D 2
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D I
C 3
2
D 3
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D ]
D 2
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1
M,/LY_HS 1
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2
13
2
8
3
9
1
31
0
15
0
2
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0
2
1
0
1
1
0
2
5
0
16
2
I
1
4O
11
15
I
12
0
1
3
22
16
5
0
5
12
12
5
1
0
0
3
12
4
9
3
9
31
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0 2 0
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0 25% 0
0 0% ?
40 18%
0 80% 0
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2 31% 3
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0 4
0 1_ 0
5 O
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0 39% 0
5 19%
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1
0
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3
12
4
9
3
9
25
61
24
89
38
54
89
46
0
0
28
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FUTURE DIRECTIONS
Future work will involve immunocytochemical studies of plasminogen activator inhibitor (PAl 1) in the same
breast tumor sections analyzed for uPA, since other laboratories have implicated an elevation of this factor
is highly significant for poor breast cancer prognosis [Janicke et al, 1991; Duffy et al, 1991; Grendahl-
Hansen et al, 1993]. It would be of interest to determine the relative expression of PAl and uPA at the
cellular level, not possible by measurements in extracts, as performed by the aforementioned reports. The
addition of uPA and PAl 1 assays to panels for other organ sites will be desirable. For example, both
prostate and bladder cancer involve metastatic progression and invasion.
The direct correlation between membrane the binding of uPA and invasive activity merits an
immunocytochemical study of the uPA receptor (uPAR); it is conceivable that levels of uPAR are an
extremely important marker for metastasis.
We would anticipate continuing long term, basic studies of the relationship between DNA replication and
uPA expression. The most significant question to be asked is whether there are control mechanisms
which down-regulate uPA during cell proliferation, and, reciprocally, up-regulate DNA synthesis and cell
proliferation with decreased uPA expression. These types of studies will necessitate in vitro experi-
mentation with cell lines, and molecular biological methods to elucidate the complex association between
transcription of uPA and the various factors required for cell cycle regulation and DNA proliferation.
DNA FLUORESCENCE (Pl)
MIN. MAX. COU_iT _ MEAN SD _HPCY
I 31 47 1315 81.8 40.9 2.7 7.01
2 45 55 15K3 9.5 55.3 5.9 11.7
3 58 87 152 9.5 75.8 4.4 3.35
LOG DNA FLUORESCENCE [Pl)
MIN. MAX. COUNT _ MEAN SD _HPCY
! X 0 13 1329 82.5 9.9 1.0 7.25
Y 3.24 1023 12.12 0.17 8.52
2 X 14 53 241 15.0 17.4 2.2 13.2
Y 3.24 1023 15.48 0.18 10.9
3 X 0 13 35 2.2 9.5 1.1 9.59
Y 0.10 3.25 1.22 0.25 4.00
4 X 14 53 2 0.1 15.1 2.0 5.07
Y 0.10 3.25 2.43 0.10 1.93
Figure 1. Bivariate plots of glioma ceils labeled with propidium iodide (PI) for DNA and
fluorescein-conjugated antibodies for urokinase (uPA) comparing the uPA and DNA fluorescence
for cells in G1 (82% of total cells), $ phase (15% of total cells), and G2 + M (22% of total) for two
glioma cell lines: CS (upper panels) and HBr09 (lower panels).
Figure 2, Confocal laser microscope 25Onto sections: _h_ough HBr65 glioma ceil,
.... _i_I • i_!iI
Figure 3. i__munofluorescence s-__ining ot CS glioma cell (:-craped from i:iask)_.u, sho_ _.;_pp_,a
membrane-bound uPA.
Figure 4. Digitized image ot CS glioma ceils showing membrane-bound uPA fluorescence.
i _ _!_ i_i_ _
_ i ii_ ii_
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Figure 5. Urokinase immunostaining and DNA replication for human gliomas. Monolayers of
cells were c;ulsed fc ° : _° witi_ {_._ M IdUrd, :_xed, denatured and immunostained with anti-uPA
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Figure 6a, HBr65 p_;8.co:#i:_e:_:_:_ch_:©mosome 10 as determined b,y FISH usina ar_
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Figure 6b. Human iymphocytes (no_mai diploid co:n_._ot) probed in the same mannew as FigGe
6a.
Figure 7a. Breast tumor section and normal kidney (positi_fe control) immunostained and
digitized using image cytometry and enhanced with pseuducolor to illustrate the u,PA in the fooi inthe tumor,
Figure 7b. Same section as 7a showing "digital slicing " to obtain all areas of equivaJent MOD
(Mean Optical Density) for positive uPA areas.
